HRCM
MDGL icon

Hood River Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hood River Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.8M Sell
169,084
-80,427
-32% -$41.2M 0.66% 51
2026
Q1 		$131M Buy
249,511
+1,951
+0.8% +$932K 1.31% 16
2025
Q4 		$144M Buy
247,560
+4,752
+2% +$2.43M 1.58% 13
2025
Q3 		$111M Sell
242,808
-1,930
-0.8% -$720K 1.31% 19
2025
Q2 		$74.1M Buy
244,738
+744
+0.3% +$222K 1.03% 33
2025
Q1 		$80.8M Buy
243,994
+116,155
+91% +$38.2M 1.38% 19
2024
Q4 		$39.4M Buy
+127,839
New +$36M 0.58% 73

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hood River Capital Management's MDGL Position: Q2 2026 in Review

Hood River Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 32% in Q2 2026, selling an estimated $41.2M and leaving 169,084 shares worth $90.8M. The position accounts for 0.66% of the portfolio, ranked #51.

Hood River Capital Management first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $144M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Hood River Capital Management held 169,084 shares of Madrigal Pharmaceuticals worth $90.8M as of Q2 2026.
  • Hood River Capital Management sold 80,427 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $41.2M.
  • Madrigal Pharmaceuticals made up 0.66% of Hood River Capital Management's portfolio in Q2 2026, its #51 holding.
  • Hood River Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Hood River Capital Management's Madrigal Pharmaceuticals position peaked at $144M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.